Nuvation Bio Inc
NYSE:NUVB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nuvation Bio Inc
NYSE:NUVB
|
US |
|
Norwegian Energy Company ASA
OSE:NOR
|
NO |
|
E
|
Encounter Technologies Inc
OTC:ENTI
|
US |
|
Bronco Billy Co Ltd
TSE:3091
|
JP |
|
Core Lithium Ltd
ASX:CXO
|
AU |
|
H
|
Henan Zhongyuan Expressway Co Ltd
SSE:600020
|
CN |
|
Intevac Inc
NASDAQ:IVAC
|
US |
|
E
|
E79 Resources Corp
CNSX:ESNR
|
CA |
|
A
|
AMMB Holdings Bhd
KLSE:AMBANK
|
MY |
|
S
|
Seojin System Co Ltd
KOSDAQ:178320
|
KR |
|
EpiCentre Holdings Ltd
SGX:5MQ
|
SG |
Nuvation Bio Inc
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 64 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The firm is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. The company is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 64 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The firm is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. The company is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.
Approval & launch: IBTROZI received full U.S. FDA approval June 11, 2025 and Nuvation treated 432 new patients from approval through year-end, including 216 in Q4.
Launch momentum: IQVIA shows prescribing roughly 6x faster than the two prior ROS1 TKI launches over their first two full quarters; management says uptake is broadening from academic centers into community settings.
Durability & differentiation: Management highlighted IBTROZI's durable activity and a selective balance of ROS1 and measured TrkB inhibition as a reason for strong intracranial control and tolerability.
Near-term revenue dynamics: Q4 product revenue was $15.7M and total Q4 revenue $41.9M; management explains a gap between new patient starts and revenue because many early starts were later-line patients who discontinue quickly.
Financial position & deals: Cash, cash equivalents and marketable securities were $529.2M at year-end; Nuvation received a ~$60M upfront from Eisai and still eligible for additional milestone payments (e.g., ~$30M on European approval).
Second program progress: Safusidenib showed encouraging activity in low-grade IDH1 glioma (Phase II: n=27, ORR 44%, median PFS not reached; 12% progression at 24 months) and a global Phase III (SYGMA, n=300) is underway with a 2029 readout.
Pipeline choices: The company discontinued DDC candidate NUV-1511, will apply learnings to next-generation DDCs and expects preclinical pipeline updates by year-end.
Guidance & capital outlook: Management said they do not anticipate needing external financing to reach profitability based on current plans and the strengthened cash position.
